NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 260 (estimated)
• Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Conditions

• Advanced Solid Tumors
• Non Small Cell Lung Cancer
• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	YL201	YL201 will be administered as IV infusion
DRUG	Ivonescimab	Ivonescimab will be administered as IV infusion.

Timeline

• Start date: 2025-10-29
• Primary completion: 2027-01-01
• Completion: 2027-12-01
• First posted: 2025-10-06
• Last updated: 2025-11-17

Locations

1 site across 1 country: China